San Francisco startup Construction Therapeutics is also working on an oral, once-each day GLP-1 drug called GSBR-1290—the drug surpassed Wall Road’s anticipations in June any time a mid-phase research showed typical weight loss of all over six% and it options to begin another mid-stage demo towards the end of this year—that founder and CEO Ra